Leadership & Pay ·
Faeth Therapeutics approves supplemental stock option grants to CEO and executives contingent on $70.00 share price target
SNSESensei Biotherapeutics, Inc.
Faeth Therapeutics, Inc. approved one-time supplemental performance-based stock option grants to CEO Anand Parikh (398,018 shares), General Counsel Christopher Gerry (84,766 shares), and SVP Finance Josiah Craver (30,824 shares) under the 2026 Equity Incentive Plan. The options vest upon achieving a $70.00 stock price hurdle within a four-year performance period. Faeth Therapeutics, Inc. is a biotechnology company focused on metabolic diseases.